Alentis Therapeutics

Today on International Vasculitis Day, we stand with patients affected by #vasculitis - a group of rare autoimmune diseases characterized by inflammation of blood vessels that can lead to fibrosis and eventually organ damage. At Alentis, we are committed to advancing innovative approaches in fibrosis, including the clinical development of a novel therapeutic for ANCA-associated vasculitis (https://lnkd.in/erjPkFpV). Together with the community, we continue working toward disease-modifying treatment options. Learn more: https://lnkd.in/eGX4ercD #InternationalVasculitisDay #VasculitisAwareness #VAM2025 #AAV #AlentisTherapeutics

📢 Publication alert! The review paper titled ‘Claudin proteins as emerging therapeutic targets for solid tumors’ was published in Nature Reviews Cancer: https://lnkd.in/e68AqjNU Claudins (CLDNs) are frequently overexpressed across different solid tumors and expression correlates with tumor subtype, grade and prognosis. Owing to their frequent overexpression and functional role in cancer biology, CLDNs have emerged as attractive therapeutic targets. The paper reviews the functional role of CLDN biology in solid tumours, summarize the clinical development of therapeutic approaches and discusses opportunities for biomarker-enriched patient selection. Collectively, it highlights CLDN targeting as a precision oncology approach relevant to multiple solid tumours. #AlentisTherapeutics #Claudin #CLDN1 #Oncology

Alentis will give an oral presentation during the Keystone Symposia on Molecular & Cellular Biology conference “Fibrosis: Cross Organ Pathology and Pathways to Clinical Development” held February 2-5 in Banff, Canada. Presenter - Geoffrey Teixeira, SVP Head of Fibrosis Abstract title - Claudin-1: a cross-organ driver of barrier dysfunction with disease-modifying and pan-organ antifibrotic potential Track - Drug development pathways for fibrosis – from mechanisms to medicine (February 5th, 2:30-4:30pm) Full program: https://lnkd.in/esypCNbM #AlentisTherapeutics #Claudin #CLDN1 #Fibrosis

As a leader in developing therapeutics for glomerulonephritis, Alentis is proud to sponsor the Glomerular Disease symposium hosted at the Royal Society of Medicine in London on January 22nd and 23rd. The event is a collaboration between the Royal Society of Medicine (RSM) Nephrology and Kidney Research UK Glomerulonephritis Clinical Study Group (GN CSG) and explores the latest advances in the treatment and pathogenesis of primary and multisystem glomerular diseases. More information: https://lnkd.in/epRFXqrA #AlentisTherapeutics #Nephrology #Glomerulonephritis

Our CEO, Mark Pruzanski, MA, MD, is scheduled to present at the J.P. Morgan Healthcare Conference on January 14 at 1:30 PM. The conference will be held January 12–15 at the Westin St. Francis Hotel in San Francisco, California. For more information visit: www.alentis.ch Looking forward to seeing you there! #AlentisTherapeutics #Healthcare #Biotech #Claudin #CLDN1 #JPMorganHealthcareConference #JPM2026

Good news! We’re delighted to welcome Bryan Yoon and Aditya Venugopal to the Alentis team. Bryan has over 20 years of experience working with life sciences companies, most recently as Chief Operating Officer and General Counsel at Terns Pharmaceuticals. Aditya brings over 15 years of industry experience, most recently serving as SVP and Head of Corporate Development at Versanis Bio. Their knowledge and experience will be instrumental in shaping the future of Alentis. Read the full press release: https://lnkd.in/eqkRvW6U #AlentisTherapeutics #Leadership #Biotech #Hello

Looking forward to attending the American Society of Nephrology – Kidney Week in Houston, Tx held Nov 5-9, 2025. Alentis is presenting two abstracts on #lixudebart, a potential pan-organ antifibrotic therapy: TH-OR040 - Targeting of CLDN1 Reduces Kidney Injury and Macrophage Infiltration in FSGS (collaboration with Pr. Tharaux / University of Paris, France and Pr. Rabelink / Leiden University, Netherlands) Nov 6, 2025 – Oral Presentation Session ‘Glomerular Precision Nephrology: Novel Mechanisms, Biomarkers, and Therapeutic Targets’ TH-PO0659 - Therapeutic Targeting of CLDN1 Reduces Glomerular Crescent Formation and Fibrosis and Preserves Renal Function in ANCA-Associated Glomerulonephritis (collaboration with Pr. Kitching / Monash University, Australia) Nov 6, 2025 – Poster Session ‘Glomerular Diseases: Immunopathogenesis and Targeted Therapeutics [PO1401-1]’ 👩🔬 Lixudebart (ALE.F02) is being studied in a Phase 2 clinical trial in patients with rapidly progressive glomerulonephritis (RPGN) due to ANCA-associated vasculitis (AAV). Learn more: https://lnkd.in/em4AU-ef #AlentisTherapeutics #Claudin #CLDN1 #ANCAVasculitis #RPGN #FSGS #Fibrosis #Nephrology #ASNKidneyWeek #ASN2025

We are proud to welcome Mark Pruzanski, MA, MD as CEO. Mark is a physician entrepreneur with more than 30 years of experience in the life sciences industry and a proven track record building and leading successful biotech companies. He most recently served as Chairman and CEO of Versanis Bio and prior to that was the founder and longstanding CEO of Intercept Pharmaceuticals. Read the full press release: https://lnkd.in/eNdSAXw4 #AlentisTherapeutics #Biotech #ChiefExecutiveOfficer #Hello

Fierce Biotech picked Alentis as one of the 2025 #Fierce15. Congrats to all other honorees, we are proud to be among the best of #biotech!

In the majority of ANCA-associated vasculitis (AAV) cases, the disease process can cause serious damage to the kidneys due to rapidly progressive glomerulonephritis (RPGN). We are currently enrolling a Phase 2 clinical study to evaluate whether lixudebart (ALE.F02), an investigational monoclonal antibody targeting Claudin-1, can preserve kidney function in patients with AAV-RPGN. The study is being conducted at hospitals in Germany, France, UK, Spain, Italy, Denmark, Czech Republic, Sweden, Switzerland and Turkey. Learn more: https://lnkd.in/erjPkFpV #AlentisTherapeutics #Nephrology #Nephrologist #Vasculitis #ANCAVvasculitis #RPGN